Breast Cancer Trial, Not Yet Recruiting NCT06903429 Sponsor: Kyungpook National University Chilgok Hospital Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Not Yet Recruiting

NCT06903429
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People aged between 20 and 70 years old.
  • Women who have been diagnosed with a primary invasive breast cancer through a biopsy.
  • Women where the cancer is suspected to have spread to the lymph nodes in the armpit, and this has been confirmed through a needle sample or biopsy.
  • People whose cancer has been clinically staged as T1 to T4, N1 to N3 (confirm with trial site for what this means in individual cases).
  • People who have been fully informed about the trial and have signed a consent form agreeing to take part.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who did not have adequate imaging of the armpit area before surgery.
  • People whose breast cancer has come back (recurrent), or who have inflammatory breast cancer.
  • People whose breast cancer has spread to other parts of the body (Stage 4).
  • People who have had an allergic reaction to any ingredients in the study drug being used in this trial.
  • People who are scheduled for a type of armpit surgery that does not involve targeting the specific area this trial focuses on (confirm with trial site).
  • People who have an active connective tissue disease, such as scleroderma or lupus, that has affected the skin.
  • People with locally advanced or inflammatory locally advanced breast cancer that cannot be treated with surgery.
  • People who have had an allergic reaction to the main ingredient or any other components of the study drug.
  • Women who could become pregnant during the trial and do not agree to use a highly effective, non-hormonal contraceptive method (such as sterilisation, an intrauterine device, complete abstinence, or a partner who has had a vasectomy) from the time of the study drug injection through to the follow-up visit.
  • Women who are currently pregnant or breastfeeding.
  • People who have taken part in another clinical trial within 12 weeks before joining this trial.
  • People whom the trial doctor considers unsuitable for participation for any other reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Korean Breast Cancer Society Study Group, Korean Breast Cancer Society Study Group

Phone: 82-53-200-2707

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Kyungpook National University Chilgok Hospital
Registry
ClinicalTrials.gov
Start date
1 May 2025
Est. completion
31 December 2026

Primary endpoints

Accuracy of the axillary lymph node targeting method; Comparison the accuracy rate between LuminoMark group and conventional group

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov